5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
April 2024 in “Liječnički vjesnik” Modern treatments can effectively regrow hair and improve life for people with alopecia areata.
September 2023 in “Acta dermato-venereologica” Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
Children with alopecia areata need supportive care and off-label treatments due to a lack of approved options.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
July 2022 in “Singapore Medical Journal” Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
March 2025 in “Clinical and Experimental Dermatology” Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
October 2024 in “Canadian Journal of Health Technologies” Olumiant should be covered for severe alopecia areata if certain conditions are met.
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
July 2025 in “Cell & Bioscience” Specific immune cells and pathways contribute to hair follicle inflammation and hair loss, suggesting potential treatments for lichen planopilaris.
February 2025 in “PubMed” Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
2 citations
,
March 2022 in “Journal of Personalized Medicine” Personalized medicine is important for treating skin disorders, with new treatments and connections to hormones and genetics being explored.
Topical treatments like minoxidil and corticosteroids are effective for hair loss, with JAK inhibitors promising for alopecia areata.
2 citations
,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
November 2025 in “Biomedicines” Targeting pyroptosis may offer new treatments for alopecia areata, but more research is needed.
October 2025 in “Cosmetics” Genetic insights can lead to personalized treatments for acne, androgenetic alopecia, and alopecia areata.
October 2023 in “International journal of biology, pharmacy and allied sciences” Personalized treatment plans combining natural and synthetic approaches are important for managing alopecia effectively.
May 2019 in “Australasian Journal of Dermatology” The document discusses hair and nail conditions, updates on treatments for alopecia, and controversies around finasteride use.
December 2025 in “Dermatology The American Medical Journal” JAK inhibitors are effective for long-term management of alopecia areata.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
20 citations
,
December 2020 in “Frontiers in Immunology” The immune processes causing VKH and vitiligo are similar in dogs and humans.
3 citations
,
June 2025 in “Archives of Dermatological Research” Biologics and JAK inhibitors may improve treatment for scarring alopecias.
4 citations
,
April 2020 in “JAAD case reports” JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
March 2026 in “International Journal of Innovative Technologies in Social Science” Vitiligo is a systemic disease with psychological effects, and new treatments focus on personalized care.